1. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, Eosinophilic inflammation in asthma. N. Engl. J. Med. 323:
1033-1039, 1990.
2. Frew AJ, Moqbel R, Azzawi M, Hartnell A, Barkans J, Jeffery PK, Kay AB, Scheper RJ, Varley J, Church MK, T lymphocytes and eosinophils in allergen-induced late-phase asthmatic reactions in the guinea pig. Am. Rev. Respir. Dis. 141: 407-413, 1990.
3. Hatzelmann A, Tenor H, Schudt C, Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br. J. Pharmacol. 114: 821-831, 1995.
4. Bleecker E, Inhaled corticosteroids: current products and their role in patient care. J. Allergy Clin. Immunol. 101: S400-S402, 1998.
5. Persson CG, Overview of effects of theophylline. J. Allergy Clin.
Immunol. 78: 780-787, 1986.
6. Rotella DP, Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. 1: 674-682, 2002.
7. Spina D, The potential of PDE4 inhibitors in respiratory disease.
Curr. Drug Targets Inflamm. Allergy 3: 231-236, 2004.
8. Giembycz MA, Phosphodiesterase-4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 59:
193-212, 2000.
9. Zhao Y, Zhang HT, O'Donnell JM, Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]-piclamilast and [3H]-rolipram. J. Pharmacol. Exp. Ther. 305: 565-572, 2003.
10. Souness JE, Rao S, Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal. 9:
227-236, 1997.
11. Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB,
anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]-rolipram binding. Biochem. Pharmacol. 51: 949-956, 1996.
12. Martin C, Goggel R, Dal P, V, Vergelli C, Giovannoni P, Ernst M, Uhlig S, Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site. Naunyn Schmiedebergs Arch. Pharmacol. 365: 284-289, 2002.
13. Kim E, Chun HO, Jung SH, Kim JH, Lee JM, Suh BC, Xiang MX, Rhee CK, Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-asthmatics. Bioorg. Med. Chem. Lett. 13:
2355-2358, 2003.
14. Peluso MR, Flavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, and modulate lipid homeostasis in adipose tissue and liver. Exp. Biol. Med. (Maywood.) 231: 1287-1299, 2006.
15. Kawai M, Hirano T, Higa S, Arimitsu J, Maruta M, Kuwahara Y, Ohkawara T, Hagihara K, Yamadori T, Shima Y, Ogata A, Kawase I, Tanaka T, Flavonoids and related compounds as anti-allergic substances. Allergol. Int. 56: 113-123, 2007.
16. Hirano T, Higa S, Arimitsu J, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Ohkawara T, Kuwabara Y, Kawai M, Matsuda H, Yoshikawa M, Maezaki N, Tanaka T, Kawase I, Tanaka T, Luteolin, a flavonoid, inhibits AP-1 activation by basophils. Biochem. Biophys.
Res. Commun. 340: 1-7, 2006.
17. Chan AL, Huang HL, Chien HC, Chen CM, Lin CN, Ko WC, Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [3H]-rolipram binding in guinea pig tissues. Invest New Drugs, in press, 2008.
18. Ko WC, Shih CM, Lai YH, Chen JH, Huang HL, Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Biochem. Pharmacol. 68:
2087-2094, 2004.
19. Kupchan SM, Bauerschmidt E. Cytotoxic flavonols from Baccharis
sarothroides. Phytochemistry 10, 664-666. 1971.
20. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW, Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography.
Am. J. Respir. Crit. Care Med. 156: 766-775, 1997.
21. Cho YS, Kwon B, Lee TH, Kim TB, Moon KA, La S, Lee J, Lee SD, Oh YM, Moon HB, 4-1 BB stimulation inhibits allergen-specific immunoglobulin E production and airway hyper-reactivity but partially suppresses bronchial eosinophilic inflammation in a mouse asthma model. Clin. Exp. Allergy 36: 377-385, 2006.
22. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F, Liu S, Huang Z, Conti M, Chan CC, Deletion of phosphodiesterase-4D in mice shortens α2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest 110:
1045-1052, 2002.
23. Hatzelmann A, Schudt C, Anti-inflammatory and immuno- modulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
J. Pharmacol. Exp. Ther. 297: 267-279, 2001.
24. Lipworth BJ, Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365: 167-175, 2005.
25. Draheim R, Egerland U, Rundfeldt C, Anti-inflammatory potential of the selective phosphodiesterase-4 inhibitor N- (3,5- dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl] -gly oxylic acid amide (AWD 12-281), in human cell preparations. J.
Pharmacol. Exp. Ther. 308: 555-563, 2004.
26. Lai CY. Machanisms of anti-asthmatic action of hesperetin in vivo and in vitro. Master thesis, Graduate Institute of Pharmacology, Taipei Medical University, 2005.
27. Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW, Torphy TJ, Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary
eosinophil influx in guinea pigs. J. Pharmacol. Exp. Ther. 270:
250-259, 1994.
28. Muller B, Lugnier C, Stoclet JC, Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction. J. Cardiovasc. Pharmacol. 16: 796-803, 1990.
29. Naccarelli GV, Goldstein RA, Electrophysiology of phospho- diesterase inhibitors. Am. J. Cardiol. 63: 35A-40A, 1989.
30. Leeman M, Lejeune P, Melot C, Naeije R, Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD. Chest 91: 662-666, 1987.
31. Fujimura M, Kamio Y, Saito M, Hashimoto T, Matsuda T, Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo. Am. J. Respir. Crit Care Med. 151: 222-225, 1995.
32. Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM, Torphy TJ, Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J.
Pharmacol. Exp. Ther. 266: 306-313, 1993.
33. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC, PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway.
Neuropharmacology 40: 262-269, 2001.
34. Robichaud A, Tattersall FD, Choudhury I, Rodger IW, Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 38: 289-297, 1999.
35. Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC, Assessing the emetic potential of PDE4 inhibitors in rats. Br. J. Pharmacol. 135: 113-118, 2002.
OO
O C H 3 H 3 C O
O H
O H
O C H 3
O
H O
O C H 3 O H O
Figure 1. Chemical structures of ayanin (mol. wt., 344) (A) and
biochanin A (mol. wt., 284.27) (B).A
B
MCh (mg/ml)
10 100
Penh (mutiple of the saline)
0.8 Ayanin 10 µmol/kg (p.o.) Ayanin 30 µmol/kg (p.o.) Ayanin 100 µmol/kg (p.o.)
***
**
**
###
###
Number of cells (x 10
3 /m Ayanin 10 µmol/kg (p.o.) Ayanin 30 µmol/kg (p.o.) Ayanin 100 µmol/kg (p.o.)
Total Mac Lym Neu Eos
** Ayanin 10 µmol/kg (p.o.) Ayanin 30 µmol/kg (p.o.) Ayanin 100 µmol/kg (p.o.)
IL-2 IL-4 IL-5 IFN-γ TNF-α
**
Biochanin A 30 µmol/kg (p.o.) Biochanin A 100 µmol/kg (p.o.)
*** *** Biochanin A 30 µmol/kg (p.o.) Biochanin A 100 µmol/kg (p.o.)
0 Biochanin A 30 µmol/kg (p.o.) Biochanin A 100 µmol/kg (p.o.)
IL-2 IL-4 IL-5 IFN-γ TNF-α
* ****** **** *
Total Mac Lym Neu Eos
*
Figure 2. Effects of ayanin (10~100 µmol /kg, p.o.) and biochanin A( 30~100 µmol /kg, p.o.) on Penh (A, D), inflammatory cells (B, E), and cytokines (C, F) in sensitized mice which received aerosolized methacholine (MCh, 6.25~50 mg/ml) 2 days after the last allergen challenge. #p < 0.05, ##p < 0.01, ###p < 0.001 when compared with the non-challenged group. *p < 0.05, **p < 0.01, ***p < 0.001 when compared with the control (vehicle) group. Each value represents the mean + SEM. The number of mice in each group was 6~11. Total: total cells; Mac: macrophages; Lym: lymphocytes;
Neu: neutrophils; Eos: eosinophils; IL: interleukin; TNF-α: tumor necrosis factor-α;
D
Total IgE (µg/ml) Ayanin 10 µmol/kg (p.o) Ayanin 30 µmol/kg (p.o) Ayanin 100 µmol/kg (p.o)
* *
OVA-specific IgE (arbitrary unit)
0
Biochanin A 30 mmol/kg (p.o.) Biochanin A 100 mmol/kg (p.o.)
###
OVA-specific IgE (arbitrary unit)
Figure 3. Effects of ayanin (10~100 µmol/kg, p.o.) and biochanin A (30~100 µmol/kg, p.o.) on total IgE (A, B, E, F), and OVA-specific IgE (C, D, G, H) in serum (A,C, E, G) and BALF (B, D, F, H) of sensitized mice which received aerosolized methacholine (MCh, 6.25~50 mg/ml) after the last allergen challenge. ##p < 0.01, ###p
< 0.001 when compared with the non-challenged group. *p < 0.05, **p < 0.01 when compared with the control (vehicle) group. Each value represents the mean ± SEM.
The number of mice in each group was 6~11.
A
Total IgG 2a (µg/ml)
Total IgG 2a (µg/ml)
0
Figure 4. Effects of ayanin (10~100 µmol/kg, p.o.) (A) and biochanin A
(30~100 µmol/kg, p.o.) (B) on total IgG2a in serum of sensitized mice which received aerosolized methacholine (MCh, 6.25~50 mg/ml) 2 days after the last allergen challenge. ##p < 0.01, ###p < 0.001 when compared with the non-challenged group. **p < 0.01 when compared with the control (vehicle) group. Each value represents the mean ± SEM. The number of mice in each group was 6~11.A
B
Duration of anathesia (min)
0 1 0 2 0 3 0 4 0 5 0
C o n tro l
A y a n in 3 0 0 µ m o l/k g (s .c .)
Duration of anathesia (min)
0 1 0 2 0 3 0 4 0 5 0
C o n tro l
B io c h a n in A 3 0 0 µ m o l/k g (s .c .)
Figure 5. Effects of subcutaneously administered ayanin (A) and
biochanin A (B) on the duration of xylazine (10 mg/kg, i.p.)/ketamine (70 mg/kg, i.p.)-induced anesthesia in mice. Ayanin and biochanin A was administered 15 min before the anesthesia. There was no significant difference when compared with the control (vehicle) group. Each value represents the mean ± SEM. The number of each group was 6~11.A
B
Log [OVA] (g/ml)
-9 -8 -7 -6 -5 -4 -3
Contraction (% 60 mM KCl)
0
Contraction (% 60 mM KCl)
0
Biochanin A 30 µM Biochanin A 100 µM
*
*
*